RECRUITING

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to understand the role of brain glucose transport in individuals with obesity and the association with cerebral hypometabolism and these individuals' response to plasma glucose elevations. The main premise is that obesity leads to reduced brain glucose transport and that we can measure this reduction with magnetic resonance spectroscopy (MRS). The secondary premises are that this reduction is driven by elevated non esterified fatty acids which act to turn on specific signaling pathways that regulate brain GLUT1 levels.

Official Title

Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism

Quick Facts

Study Start:2020-12-08
Study Completion:2025-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04328337

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18-45 years
  2. * HbA1C \<6.5%
  3. * Normal weight individuals: BMI 17-25 kg/m\^2
  4. * Obese individuals: BMI \>30 kg/m\^2
  1. * Creatinine \>1.5mg/dL
  2. * Hematocrit \<35% for females and \<39% for males
  3. * ALT and AST \>2.5X upper limit of normal
  4. * Abnormal TSH
  5. * Abnormal PT/PTT/INR
  6. * Triglycerides \>200 mg/dL
  7. * Known hepatic, gastrointestinal, renal, neurologic, psychiatric, cerebrovascular disease
  8. * Uncontrolled hypertension
  9. * Current or past 3 months use of ketogenic diet
  10. * Use of any medications, vitamins, or supplements that can alter cerebral metabolism or lipids
  11. * Smoking
  12. * Current or recent steroid use in last 6 months
  13. * \>5% body weight change in last 6 months
  14. * Illicit drug use/alcoholism
  15. * Inability to enter MRI/MRS
  16. * For women: pregnancy, seeking pregnancy, or breastfeeding

Contacts and Locations

Study Contact

Joseph Palmiotto
CONTACT
919-966-9184
joseph_palmiotto@med.unc.edu
Cassandra Donahue, RDN, LDN, CDCES
CONTACT
984-974-3001
cassandra_donahue@med.unc.edu

Principal Investigator

Janice Jin Hwang, MD, MHS
PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill

Study Locations (Sites)

Biomedical Research Imaging Center Marsico Hall (UNC)
Chapel Hill, North Carolina, 27514
United States
Clinical and Translational Research Center (CTRC) Burnett-Womack Building (UNC)
Chapel Hill, North Carolina, 27514
United States

Collaborators and Investigators

Sponsor: University of North Carolina, Chapel Hill

  • Janice Jin Hwang, MD, MHS, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-12-08
Study Completion Date2025-06-01

Study Record Updates

Study Start Date2020-12-08
Study Completion Date2025-06-01

Terms related to this study

Additional Relevant MeSH Terms

  • Obesity